UK markets closed

Hutchison China MediTech Limited (HCM.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
226.50+9.50 (+4.38%)
At close: 05:09PM GMT
Full screen
Previous close217.00
Open224.00
Bid226.50 x 0
Ask229.50 x 0
Day's range219.19 - 232.00
52-week range130.00 - 541.00
Volume416,439
Avg. volume197,836
Market cap1.959B
Beta (5Y monthly)0.58
PE ratio (TTM)N/A
EPS (TTM)-20.10
Earnings date01 Mar 2023 - 05 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est3.91
  • Globe Newswire

    HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals

    Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today provides a corporate and strategic update, following an in-depth evaluation of the business. In response to the challenging market conditions currently affecting the global biopharmaceutical sector, HUTCHMED has taken a numb

  • Globe Newswire

    HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

    — Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary endpoint, was not statistically significant — — Safety findings consistent with fruquintinib known profile — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces initial results from FRU

  • Globe Newswire

    HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China. The first patient in China received the first dose on October 27, 2022. The study is a randomized, open-label, active-controlled study to evalu